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variables. RESULTS: Expenditures on medicines declined due to
negative impact of EML on quantities of medicines utilized per
capita as well as on real prices. The quantities declined on
average by 1.7 DDDs per capita per year. The medicine price
reduced on average by about US $0.0013 per deﬁned daily dose.
The real cost saved for the years 2000 to 2003 was about US $
5.9 million. The EML was effective in shifting all prescribing
indicators towards the standard values. CONCLUSIONS: The
PMOH should allocate more resources for pharmaceutical
budget in the future. The EML was successful in containing med-
icine cost, and careful review and update of EML should further
increase the savings. The development and implementation of
antibiotic medicine policy is an urgent need. Introduction of
treatment protocols for the most common diseases, and con-
tinuous education on rational medicine use for medical staff 
is required.
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OBJECTIVE: Mandatory generic substitution of prescribed
drugs aiming to moderate the cost increase of pharmaceuticals
within the pharmaceutical beneﬁts scheme, PBS, was introduced
in October 2002. The study aims to investigate if the introduc-
tion of generic substitution had an impact on the development
of drugs costs in Sweden for prescribed drugs within PBS and in
total. METHODS: Data on the sales of pharmaceuticals to each
county council and to the country in total was obtained. Data
comprised both total sales (prescriptions, hospitals sales and over
the counter sales) and sales of prescribed drugs within the PBS
was used for the period January 2000 to May 2005. Expendi-
ture data was expressed as retail prices excluding VAT per 1000
inhabitants in Swedish krona (SEK). Interrupted time series
analysis was used to investigate effects related to generic substi-
tution. RESULTS: The county councils’ total cost for pharma-
ceuticals increased from 230 SEK/inhabitants in January 2000 to
280 SEK/inhabitant in May 2005. The county councils’ average
monthly costs for PBS pharmaceuticals lay in three segments one
had a constant cost of ~40 SEK/inhabitant over the study period,
the second segment increased from ~140 SEK/inhabitant in 2000
to ~170 SEK/inhabitant in late 2002 where it stabilized and the
third segment ~190 SEK/inhabitant in 2000 and increased to
~210 SEK/inhabitants in late 2002 and after that it was constant.
Generic substitution was associated with reduced the slope of
increase of costs for drugs within the PBS for the whole country
and several of the county councils according to preliminary
analyses. This was also seen for several of the county councils’
total costs immediately after the introduction of generic substi-
tution. CONCLUSIONS: Preliminary analyses show that generic
substitution had an impact in the pace of increase of pharma-
ceutical expenditures.
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OBJECTIVES: The aim of this study is to analyse the small are
inequalities in the health insurance reimbursement of drugs in
Hungary. METHODS: Data derives from the central database
of the Hungarian National Health Insurance Fund Administra-
tion (OEP) covering the year 2003 and containing all the drug
reimbursement information from the whole country. For the
analysis we used three different kinds of drug expenditures
according to the source of funding: health insurance reimburse-
ment (paid by OEP), maximum reimbursement for socially hand-
icapped (coming from state budget), co-payment of patients
(paid out-of-pocket of patients) for subsidized drugs. The statis-
tical analysis was carried out with SPSS version 12.01. Small
areas refer to the postal code (zip code) districts of Hungary and
the patients were assigned to small areas according to their 
permanent address. The Geographical Information system (GIS)
analysis was carried out by the MapInfo Professional software
version 7.5. RESULTS: The health insurance reimbursement of
drugs paid by the National Health Insurance Fund Administra-
tion is signiﬁcantly higher (p < 0.05) in the southern and eastern
part of Hungary. The maximum reimbursement for socially
handicapped paid by the National Health Insurance Fund
Administration is also signiﬁcantly higher (p < 0.05) in the
eastern part of Hungary. The co-payment of patients is signiﬁ-
cantly higher (p < 0.05) in the western and central regions of
Hungary. The results are presented on GIS maps also. CON-
CLUSIONS: The GIS analyses help to identify the geographical
inequalities of the drug expenditures coming from different
sources. In the more developed regions (western and central
regions) the willingness and ability to pay the co-payment is
higher. In the less developed regions of Hungary (northern and
eastern regions) the people more rely on the reimbursement for
socially handicapped ﬁnanced from the state budget.
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OBJECTIVE: To investigate whether patients with a $1,000
annual prescription drug beneﬁt cap reduced their drug con-
sumption prior to exceeding the cap threshold. Previously, we
found that the drug cap reduced overall drug consumption
during the year. METHODS: All 183,640 subjects were 65+
years with Medicare insurance, had tiered copayments ($10 for
generic & $15–35 for brand drugs), and were members of an
integrated, prepaid delivery system: 146,050 subjects had an
annual $1000 drug beneﬁt limit; and 37,590 subjects had no
beneﬁt limit (because of supplementary insurance from former
employers rather than individual choice). To compare drug con-
sumption (measured in dollars) below the cap amount, we exam-
ined the risk of cap and non-cap subjects consuming $250, $500,
$750, and $1000 in 2003 using proportional hazard models for
each of these thresholds. We adjusted for age, gender, race/eth-
nicity, brand copayment amount, prior visits, socioeconomic
status, comorbidity, and having a regular primary care provider.
RESULTS: Among the 183,640 subjects, 16,657 (11%) of sub-
jects with a cap and 7,888 (21%) of subjects without caps
exceeded the $1,000 cap threshold during 2003. After adjust-
ment for covariates, subjects with a cap were signiﬁcantly less
likely to exceed the $1,000 cap threshold (HR = 0.61, 95% CI:
0.56–0.66), compared with subjects without a cap. Similarly,
subjects with a cap were signiﬁcantly less likely to exceed lower
drug consumption thresholds during the year, compared with
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subjects without a cap: HR = 0.75 for $750 (95% CI:
0.70–0.80); HR = 0.80 for $500 (95% CI: 0.75–0.85); HR =
0.81 for $250 (95% CI: 0.77–0.85). CONCLUSIONS: These
preliminary analyses indicate that patients with annual drug
beneﬁt caps appear to anticipate exceeding the beneﬁt limit, and
reduce their drug consumption prior to reaching the cap amount.
Further research is needed to assess how patients reduce their
drug consumption and the clinical and economic impact.
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OBJECTIVE: This paper compares the prices of top selling
generic drugs in Canada with prices for comparable generics in
the United States (updating a 2002 study). METHODS: We 
compared manufacturer prices of 21 top selling (in 2004) generic
prescription medicines in Canada that were marketed in both
Canada and the US. Sources of Canadian prices included gov-
ernment reimbursed prices for Quebec, British Columbia and
Saskatchewan. US prices were sourced from the Federal Supply
Schedule (FSS) and three state Medicaid program Maximum
Allowable Cost (MAC) lists. The prices of a subset of 11 drugs
that appeared in both studies were compared to investigate
trends. RESULTS: Of the 21 leading generic drugs, 20 had higher
prices in Canada. Canadian prices were higher than US prices on
all measures: Mean: +238%; Weighted Mean: +259%, Median
+128%. If Canadians could access FSS prices for the 21 sample
drugs, annual savings would exceed C$440 million. If the price
differences observed are extrapolated to all generic drugs sold 
in Canada, annual savings could exceed C$1 billion. Canadian
prices were also higher than state Medicaid MAC prices: Mean:
+44%; Median: +15%. When comparing the 11 drugs that 
were included on both studies, a clear trend emerges: US prices
have decreased 31% since 2001, while Canadian prices have
remained stable. CONCLUSIONS: US prices of top-selling
generics are lower than those in Canada and the price gap is
widening. US generic prices are now on average 238% lower
than those in Canada compared to 155% in 2001. Provincial
government policies that establish Canadian generic prices at a
percentage of branded products are one of the factors that
appear to discourage price competition. Unlike Canada, US
generic prices typically fall over time as more manufacturers
enter the market and compete for government contracts and 
formulary listings.
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OBJECTIVE: To evaluate the role of pharmacoeconomics in the
Greek pharmaceutical environment. METHODS: The existing
pharmaceutical reimbursement system in Greece and the pro-
posal for the new pharmaceutical policy, announced in Novem-
ber 2004 by the Greek Ministry of Health and Social Solidarity
were examined. RESULTS: The current reimbursement system
in Greece consists of a positive reimbursement list. The main cri-
terion for a product to be accepted for reimbursement is its daily
drug cost in comparison to the average drug cost of the thera-
peutic cluster to which it belongs. Nevertheless, other factors are
also taken into account in order to approve reimbursement, such
as the non-mandatory submission of pharmacoeconomic studies,
even though their role in a positive or negative reimbursement
decision is not clariﬁed. The new system announced by the Min-
istry states that it plans to abolish the reimbursement list. In the
place of the current reimbursement system it proposes, among
other measures that aim to contain costs and alleviate patient
burden, the implementation of a rebate system where drugs are
grouped into therapeutic clusters and a reference price is calcu-
lated for each cluster. Pharmaceutical companies will return the
weighted difference between their products’ price and the refer-
ence price to social insurance organizations. The proposal states
that rebate levels can be adjusted based on pharmacoeconomic
evidence in order to reward cost-effective therapies. Addition-
ally, the proposal announces the establishment of a Health care
Technology Evaluation Agency that will evaluate technologies
and produce guidelines based on evidence based medicine and
cost-effectiveness parameters. This Agency will also evaluate
pharmaceconomic evidence in cases where there is a need to
adjust rebate levels for speciﬁc products. CONCLUSIONS: At
present, pharmacoeconomics play a limited role in the reim-
bursement of pharmaceuticals in Greece. The new pharmaceuti-
cal policy proposal reinforces the role of pharmacoeconomics in
Greece, which is a welcome development.
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OBJECTIVES: To cut the escalating costs for pharmaceuticals
the responsibility for costs of outpatient prescription drugs was
decentralized from the government in Sweden to the county
councils in 2002. The study aims to investigate if the introduc-
tion of decentralized responsibility had an impact on the phar-
maceutical cost development in Sweden. METHODS: Monthly
sales data, on the pharmaceutical beneﬁts scheme, PBS, to each
county council was obtained for the period January 2000 to May
2005. Interrupted time series analysis was used to investigate 
the effects of the introduction of decentralized responsibility on
pharmaceutical costs in both total sales and sales of prescription
drugs within total and within the PBS. This was investigated both
on country level and with comparisons between county councils
with different budget models for the decentralized responsibility.
The investigation is continuing. RESULTS: Analyses show 
that there was no signiﬁcant change in the cost trend associated
with the introduction of decentralized responsibility for costs of
outpatient prescription drugs. The county councils’ costs of 
prescribed drugs covered by the PBS were on three levels;
€19.5/inhabitant in 2000 and €23.9/inhabitant in May 2005, the
second €15.7/inhabitant in 2000 and €19.5/inhabitant in May
2005 and the third €3.6/inhabitant in 2000 and €6.0/inhabitant
in May 2005. All county councils remained on the same level
throughout the study period. The budget model for outpatient
prescription drugs had no impact on the level of costs. When
considering total drug expenditures including inpatient drug
costs the three segments diminish and all county councils 
are gathered between €21.7–26.0/inhabitant in 2000 and
€28.2–34.7/inhabitant in May 2005. CONCLUSIONS: Pharma-
ceutical costs increased despite the introduction of decentralized
cost responsibility for drugs in outpatient care. The budget
models had no clear impact on the cost trend.
